NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that Jennifer Fulk, Chief Financial Officer, will be participating in a fireside chat at Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023.
About Talkspace
Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including video, text or audio chat sessions and/or unlimited text messaging.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 92 million lives at December 31, 2022, through our partnerships with employers, health plans, and paid benefits programs.
Contacts
For Investors:
Sloane & Co.
Neal Nagarajan
(301) 273-5662
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
SKDK
John Kim
(310) 997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.49 |
Daily Change: | -0.03 -1.00 |
Daily Volume: | 5,717,052 |
Market Cap: | US$415.790M |
May 06, 2025 February 20, 2025 December 10, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load